Have a feature idea you'd love to see implemented?
Let us know!
ACAD Acadia Pharmaceuticals Inc
Price (delayed)
$17.22
Market cap
$2.87B
P/E Ratio
22.08
Dividend/share
N/A
EPS
$0.78
Enterprise value
$2.74B
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who
Highlights
The net income has surged by 186% year-on-year
The EPS has soared by 185% YoY
The quick ratio is up by 9% since the previous quarter but it has declined by 7% year-on-year
The gross margin has declined by 4.5% year-on-year
Key stats
What are the main financial stats of ACAD
Market
Valuations
Earnings
Shares outstanding
166.39M
Market cap
$2.87B
Enterprise value
$2.74B
Price to earnings (P/E)
22.08
Price to book (P/B)
4.95
Price to sales (P/S)
3.08
EV/EBIT
20.06
EV/EBITDA
18.4
EV/Sales
2.95
Revenue
$929.24M
Gross profit
$851.31M
Net income
$128.51M
EBIT
$136.69M
EBITDA
$149M
Free cash flow
$202.66M
Per share
Balance sheet
Liquidity
EPS
$0.78
EPS diluted
$0.78
Free cash flow per share
$1.22
Book value per share
$3.48
Revenue per share
$5.6
TBVPS
$5.25
Total assets
$976.87M
Total liabilities
$399.69M
Debt
$40.42M
Equity
$577.18M
Working capital
$444.34M
Debt to equity
0.07
Current ratio
2.29
Quick ratio
1.99
Net debt/EBITDA
-0.83
Margins
Efficiency
Dividend
EBITDA margin
16%
Gross margin
91.6%
Net margin
13.8%
Operating margin
12.1%
Return on assets
14.7%
Return on equity
25.8%
Return on invested capital
43%
Return on capital employed
21.6%
Return on sales
14.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACAD stock price
How has the Acadia Pharmaceuticals stock price performed over time
Intraday
0.88%
1 week
2.93%
1 month
6.23%
1 year
-44.68%
YTD
-45%
QTD
11.96%
Financial performance
How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$929.24M
Gross profit
$851.31M
Operating income
$112.24M
Net income
$128.51M
Gross margin
91.6%
Net margin
13.8%
The net income has surged by 186% year-on-year
The operating income has soared by 173% YoY
The net margin has soared by 159% YoY
The operating margin has soared by 150% YoY
Growth
What is Acadia Pharmaceuticals's growth rate over time
Valuation
What is Acadia Pharmaceuticals stock price valuation
P/E
22.08
P/B
4.95
P/S
3.08
EV/EBIT
20.06
EV/EBITDA
18.4
EV/Sales
2.95
The EPS has soared by 185% YoY
The company's equity has surged by 59% YoY and by 12% QoQ
ACAD's price to book (P/B) is 39% lower than its 5-year quarterly average of 8.1 and 30% lower than its last 4 quarters average of 7.0
ACAD's P/S is 66% below its 5-year quarterly average of 8.9 and 26% below its last 4 quarters average of 4.1
ACAD's revenue is up by 47% YoY and by 4.3% QoQ
Efficiency
How efficient is Acadia Pharmaceuticals business performance
ACAD's return on invested capital has surged by 192% year-on-year and by 174% since the previous quarter
The ROS has soared by 188% QoQ and by 171% YoY
The ROE has soared by 166% YoY
Acadia Pharmaceuticals's return on assets has surged by 162% YoY
Dividends
What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACAD.
Financial health
How did Acadia Pharmaceuticals financials performed over time
The total assets is 144% more than the total liabilities
The total assets has soared by 54% YoY and by 7% from the previous quarter
The total liabilities has increased by 48% YoY
The debt is 93% lower than the equity
The company's equity has surged by 59% YoY and by 12% QoQ
The debt to equity has declined by 46% year-on-year and by 22% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.